Showing results (41-50 of 288) with videos related to

Sort By:
Pageof 29
Blood Advances|September 2, 2021
Racial and ethnic enrollment disparities and demographic reporting requirements in acute leukemia clinical trialsAndrew Hantel, Marlise R Luskin, Jacqueline S Garcia, et al.
International Journal of Oncology|April 6, 2006
Quantitative real-time RT-PCR monitoring of BCR-ABL in chronic myelogenous leukemia shows lack of agreement in blood and bone marrow samplesWendy Stock, Daohai Yu, Ted Karrison, et al.
Cancer|September 14, 2016
Adoption of pediatric-inspired acute lymphoblastic leukemia regimens by adult oncologists treating adolescents and young adults: A population-based studyLori Muffly, Daphne Lichtensztajn, Parveen Shiraz, et al.
Expert Opinion on Drug Metabolism & Toxicology|July 6, 2023
Asparaginase toxicity in Hispanic adult and pediatric patients with acute lymphoblastic leukemia: current understandingAmani Alqahtani, Diala Alhousari, Amir Ali, et al.
Leukemia|December 28, 2023
Loss of thymocyte competition underlies the tumor suppressive functions of the E2a transcription factor in T-ALLGeoffrey Parriott, Emma Hegermiller, Rosemary E Morman, et al.
Blood|May 27, 2008
What determines the outcomes for adolescents and young adults with acute lymphoblastic leukemia treated on cooperative group protocols? A comparison of Children's Cancer Group and Cancer and Leukemia Group B studiesWendy Stock, Mei La, Ben Sanford, et al.
Biorxiv : the Preprint Server for Biology|May 10, 2023
Loss of thymocyte competition underlies the tumor suppressive functions of the E2a transcription factor in T lymphocyte acute lymphoblastic leukemiaGeoffrey Parriott, Emma Hegermiller, Rosemary E Morman, et al.
Translational Oncology|October 27, 2015
Targeting Suppressor of Variegation 3-9 Homologue 2 (SUV39H2) in Acute Lymphoblastic Leukemia (ALL)Martin Mutonga, Kenji Tamura, Gregory Malnassy, et al.
Leukemia & Lymphoma|January 15, 2009
Allogeneic stem cell transplantation with alemtuzumab-based conditioning for patients with advanced chronic myelogenous leukemiaXavier Poiré, Andrew Artz, Richard A Larson, et al.
British Journal of Haematology|December 11, 2023
Durable responses in acute lymphoblastic leukaemia with the use of FLT3 and IDH inhibitorsRafael Madero-Marroquin, Adam S DuVall, Caner Saygin, et al.
Pageof 29